Syros completed the merger with TYME in a $60m deal.

Syros, a firm engaged in the development of medicines that control the expression of genes, completed the merger with TYME, an emerging biotechnology company, in a $60m deal. “Following an extensive review of numerous strategic alternatives, it was clear that the proposed merger with Syros was the best option for our shareholders. The team at Syros shares our unwavering commitment to develop medicines that make a profound difference in patients’ lives. Syros has a robust pipeline with its lead program in Phase 3, an experienced management and board, and now is well capitalized to execute on its clinical endeavors. Additionally, Syros will continue our work of evaluating the best path forward for the SM–88 program," Richie Cunningham, TYME CEO.